Search 

Swiss- Israeli based company, fuses the know how of specialists in the pahrmacology and delivery fields with the aim to bring to the market novel drugs based on cannabinoid molecules as stand alone, and synergistic combinations with proper drug delivery technologies

DataHow AG is a spin-off company from ETH Zurich specialized in data analytics and process modeling for the process industry with a particular focus on the production of biopharmaceuticals.

We offer digital solutions and consulting for process screening, monitoring, optimization, control and scale-up. Our goal is to reduce the effort, risks and costs in process development and manufacturing as well as to gain deep understanding of the complex processes.

DataHow emerged in 2017 from the research group of Prof. Morbidelli at ETH Zurich based on the activities of Dr. Alessandro Butté, Michael Sokolov and Fabian Feidl.

Dolopharm is a drug development company from Charité, Berlin, with a focus on GPCR-targeted therapies. Our first pipeline candidate NFEPP for the treatment of severe acute and chronic pain has shown impressive performance in several pre-clinical trial models. In contrast to standard medications, such as opioids, NFEPP avoids drug addiction, respiratory depression, constipation and other known side effects thus representing a potential breakthrough medication for many pain related indications. 

Drug Development

New Drugs

Pain therapy

Start-up seeking for initial financing

We are currently looking for investors to finance our clinical phase I studies in post-operative pain treatment after knee surgery. So, feel free to talk to us and find out, how to join this outstanding investment opportunity.

Retinitis Pigmentosa (RP), Leber’s Congenital Amaurosis (LCA) and Stargardt’s Disease (STGD) are rare eye diseases leading to severe vision impairment or blindness.  Within the eye, they cause degeneration of the photoreceptors responsible for conversion of light into signals to be sent to the brain. The conditions are inherited and caused by ~250 different gene mutations. They affect a combined 450,000 people within the EU, Japan and the US.
To date, no treatment is available for RP, LCA and STGD.
Mireca wants to develop drug candidate LP–DF 003 which uses a novel approach for the treatment of the conditions. In contrast to current gene therapies, which address specific gene mutations, Mireca’s approach is significantly broader and assumed suitable to target at least one third of the various gene mutations.
Based on the promising outcomes of the EU (FP7) funded DRUGSFORD project, Mireca benefits from completed pre-clinical pharmacology and initial safety testing, an existing orphan drug designation granted by the EMA, a GMP-compliant production process, 3 patent applications and exclusive licensing agreements.
Beyond currently planned product developments, Mireca has access to a platform technology for the potential treatment of several neurodegenerative diseases.
Mireca has been set up as a German limited liability company (“GmbH”) located in Tuebingen (~40 kilometers south of DE-Stuttgart). Mireca’s experienced international management team combines broad and deep scientific as well as business experience.
Mireca wants to transition LP-DF003 into clinical studies and aims to obtain market authorizations for RP, LCA and STGD treatment products starting in the year 2024.

Mireca´s lead compound is a small molecule intended for the treatment of rare and currently untreatable forms of hereditary blindness.

Mireca currently runs a Series A funding round to initiate clinical studies.

Musli Thyropeutics is a clinical stage pharmaceutical company addressing high-grade cancers. The company's patented fix-dose combination is based on recent scientific findings. Musli is targeting Glioblastoma Multiforme and Brain Metastases as-well-as Lung cancer and other aggressive high-grade cancers. Musli is preparing for Phase 2/3 clinical trials starting in 2018. Our innovative adjunct approach to current standard of care is expected to facilitate quick penetration to some of the largest markets in oncology, composing a multi-billion opportunity.